Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There are 500 people in the US with wolfram's and well it is complicated, but any indication for this entity is five to 10 years away.
AMBS breaks support at THREE CENTS. We are now in the high Two cents range. Ok, is ANYONE ABOVE WATER?
I didnt think so. Maybe one or two, but that is it. Most notably GC is down about 75% having bought repeatedly around nine cents. Good job fearless leader GC.
While averaging in here is well, fine, as long as you take a couple of months to average in, there is more dilution coming.
I was thinking of pulling the trigger at 3.2 cents, but well, I didn't.
THIS IS WHAT AN RS ALMOST ALWAYS DOES TO YOUR PPS.
And oh by the way, $4 is just a weak armed rotator cuff torn throw away from here.
When they are finished studying Lympro, they will continue with PET scans because you can see the amyloid with PET scans and follow its progression.
Also, the data presented was old and not competitive with PET scans.
Now, Lympro could have some use in finding subjects for testing, if it is cost effective. THat is the only use it will have. The numbers on Lympro have never changed, they remain about the same or got a little worse, regardless of how the company tried to spin it.
GC lying once again. He had new data to tell us all, after the multivariate analysis which took a day to do, and was being shopped to KOLs privately, but would have increased the pps if they had released it to the press, and increased the interest of the KOLs at the same time.
oh GC, oh my
These are the inadequate numbers from last year. yawn. pr attempt at increaasing the pps. It did not work.
Unless you are a private investor, and this is not actually a publicly traded stock, the IPO happened a long time ago, and many other O's as well, on a daily basis.
Any Public offering will be a secondary offering.
Oh.
Nevertheless, the word IPO is out there, because it does sound good. another misstep, and misleading statement on the part of gc.
One of my favorite misleading statements was that recent one that claimed there would not be dilution except that there would be dilution, or words to that effect.
Really big in the volume today.
The pps is currently .038 cents, awaiting the next diluting event. There is one really big one coming up.
I posted the THREE MILLION SHARES before.
They are saying that while the stock can be converted at $9. This is written so that "Conversion premiums" will kick in if the stock does not reach that level, down to a VERY LOW LEVEL, almost DOUBLING the current float of 7 million shares to 10 million shares. ( keeping in mind I used round numbers )
Interesting.
IOW, what if the stock never got back to six cents again?
How does that work exactly, I've never seen anthing like that personally. Is the stock worth $9 when they get it, or do they have to wait until it is $9 to convert?
We are offering directly to an institutional investor for total gross proceeds of $2,000,000 435 shares of Series G Preferred Stock and up to 241,667 shares of common stock issuable upon conversion of 435 shares of Series G Preferred Stock and up to 3,000,000 shares of common stock that may be issued as a conversion premium, or may be issued, at our sole and absolute discretion, in payment of dividends on such shares of Series G Preferred Stock.
And the closing price for the day July 8, 2015,3.16666 cents on a split adjusted basis.
Is ANYONE above water?
And in other news, MME ( Membrane metallo endopeptidase ) which is involved in AD, cancer, Heart Failure and so on and so forth is now the target of the next multi billion dollar drug approved by the FDA yesterday.
Yes Scarlet, there is hope for MANF, if someone throws a billion dollars at it and spends about ten years.
Note to admin, I did not mention another product, only that MME and MANF are active in many similar situations for TOTALLY different reasons.
The MME inhibitor was approved by the FDA yesterday as a blockbuster drug for Heart Failure. You will be hearing a LOT about MME, and you will be hearing some about MANF. I wonder just how much though.
Pps THREE CENTS. Who is above water?
$5 / 150 = 3.333333 cents. That is a lot of sense. 45000 volume times 150 equals 6750000. Pretty strong volume for AMBS. or something like that.
actually a very good trading opportunity is coming up.
There is resistance ALL THE WAY UP to $30, or .20 cents. That is a lot of resistance.
And there is more downside than upside at the moment.
Just think if you sold at twenty cents. That would have been something. Now you can buy at around three cents.
http://stockcharts.com/freecharts/gallery.html?s=AMBSd
And the chart looks like it is going to $4 as well. Get ready for a tremendous buying opportunity.
The only problem with $4 is that it is below THREE CENTS. And the pps is currently in the HIGH three cent range.
If someone gives AMBS one BILLION dollars, then they might find out if MANF is the answer for DM. Given that there are many alternatives, and what not it is very unlikely that a once a month 100000 treatment could be accepted for DM, a very common disease.
A schedule like that was being thrown around a couple of years ago. It is very unlikely that anything more than interest will be shown in MANF for DM in the next generation or so.
It is much higher than that, almost a certainty. The questions are, will anyone notice, and will they stay there?
NOTE THE DATE OF THE TWEET, JULY 2014. That was around the AAIC.
That is easy. If the transaction involves dilution, then the pps will go down. If the transaction involves another company taking on risk for a change then the pps will go up.
And the $3 million getting absorbed by the market comes at a critical time when the company seriously needs the money from an IPO to buy ESS and the Georgetown test and so on. So, that is a pretty interesting sale.
this post.
Actually it reflects no DD. Read S1 and previous posts.
Oh.
Buying in the threes is fine. Don't get me started with the AAIC. Uplisting will be good. They need to get $$$ without dilution however. The recent lows will be revisited soon.
Yep, AMBS will get orphan for PD and MANF and get revenue this year. LOL. I wonder where I read that before.
Truth. MANF could be useful but it will take a Billion dollars to find out, and in many indications, there are better alternatives.
I could go on. and will at a later date.
That said, buying in the Threes is always a good idea. I expect that when Rubinfeld sells his shares ( which he is about to do ) the pps will go back to the threes.
In the terms of the RS that means a pps between $4.50 and $6.00. There is a support at three cents, so buying at $5 is very reasonable.
This prospectus relates to the offer and sale of up to 520,344 shares of common stock, par value $0.001, of Amarantus BioScience Holdings, Inc., a Nevada corporation, by the selling stockholders identified on page 17 of this prospectus.On June 9, 2015, we effected a 1-for-150 reverse stock split of our issued and outstanding common stock and our authorized common stock.
Let's all sell BEFORE the IPO so we can make a lot of money. Or something like that.
It is an insider sale.
We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
One of the selling stockholders, Lincoln Park Capital Fund, LLC, or “Lincoln Park”, is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended. The selling stockholders, including Lincoln Park, may sell the shares of common stock described in this prospectus in a number of different ways and at varying prices. See “Plan of Distribution” for more information about how the selling stockholders may sell the shares of common stock being registered pursuant to this prospectus.
We will pay the expenses incurred in registering the shares, including legal and accounting fees. See “Plan of Distribution”.
Our common stock is currently quoted on the OTC Markets under the symbol “AMBS”. On June 22, 2015, the last reported sale price of our common stock on the OTC Markets was $5.96.
Selling Stockholder Shares
Beneficially
Owned
Before this
Offering Percentage of
Outstanding
Shares
Beneficially
Owned Before
this
Offering(1) Shares to be
Sold in this
Offering Percentage of
Outstanding
Shares
Beneficially
Owned After
this Offering
(2)
Lincoln Park Capital Fund, LLC (3) 136,140 1.90 % 163,678 0
Memory Dx, LLC (4) 0 * 30,000 0
PGI Drug Discovery, LLC (5) 26,667 0.38 % 26,667 0
Dominion Capital, LLC (6) 393,425 4.99 % 138,889 *
Dustin Ray Johns (7) 20,486 0.29 % 20,486 *
International Infusion, Inc. (8) 374,569 5.07 % 54,514 *
Joseph Rubinfeld (9) 31,182 0.44 % 1,389 *
Nicholas Nurse (10) 8,333 0.12 % 8,333 *
Robert F. Johnston Living Trust (11) 20,833 0.29 % 20,833 *
Gemini Master Fund, Ltd. (12) 55,556 0.78 % 55,556 *
TOTAL 520,345
* Less than 1%
(1) Based on 7,067,610 outstanding shares of our common stock as of June 16, 2015.
(2) Assumes the sale of all the shares offered by the selling stockholders.
pps is just less than four cents as we enter the trading day, June 23. 2015. 7.5 = five cents, $6 = four cents. The pps is less than four cents by a smidge.
IOW, the pps remains in the high three cent range.
Congrats to all of you in the AMBS family. Especially GC the CEO all of his insider purchases are severely under water.
That should say, in reverse split shares. In other words, there was a rare day when real money actually changed hands over AMBS.
The volume is over Three million, un reverse split shares.
Ok, the pps is BACK up to FOUR CENTS ($6). How many people are in the green on this stock, pretty much only those that bought in the low $fives and what not.
Note, most of GC's insider purchases are around nine cents. oops.
AMBS is UP today, by One penny. It is good to see that ONE penny is a 0.18% change in the pps.
Go AMBS, you have a green day.
So Far.
http://stockcharts.com/freecharts/gallery.html?s=AMBSd
The chart is now a real chart as well. However the chart met criteria for a triple bottom breakdown, on Tuesday. The target price is $4.50.
There have only been a couple of days where the volume was higher than 75 million, the equivalent of a post split adjusted volume of 500000
I do not think many will be buying, not since the average volume is shown to be 33000 with a $5 pps. Today they are selling off on twice the daily volume and the volume is just 57K so far.
And yes, this is a wonderful trading stock. $3 may be the buy point.
Frankly, the level of PAIN is high, so this may be a tradable pps, although most definitely not for the faint of heart.
Insider buys have been an excellent sell signal.
It is the hour of truth. Sell or hold or buy more or wait for the pps to go to $3 or so.
the equivalent pps is .036 with the post split price of $5.42. That means that everyone except the people who bought in 2012 are under water. That is especially true about every GC purchase ( The CEO ) His purchases were excellent sell signals.